Almokalant

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573106

CAS#: 123955-10-2

Description: Almokalant is a drug used to treat heart arrhythmia by blocking potassium channels. It has been found to have teratogenic effects in rats.

Chemical Structure

img
Almokalant
CAS# 123955-10-2
Instruction

Theoretical Analysis

MedKoo Cat#: 573106
Name: Almokalant
CAS#: 123955-10-2
Chemical Formula: C18H28N2O3S
Exact Mass: 352.18
Molecular Weight: 352.490
Elemental Analysis: C, 61.33; H, 8.01; N, 7.95; O, 13.62; S, 9.10

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Almokalant

IUPAC/Chemical Name: 4-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile

InChi Key: ZMHOBBKJBYLXFR-BPNWFJGMSA-N

InChi Code: 1S/C18H28N2O3S/c1-3-11-24(22)12-5-10-20(4-2)14-17(21)15-23-18-8-6-16(13-19)7-9-18/h6-9,17,21H,3-5,10-12,14-15H2,1-2H3/t17-,24?/m1/s1

SMILES Code: CCC[S+]([O-])CCCN(CC)C[C@@H](O)COc1ccc(cc1)C#N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 352.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B. Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica. 2003 Nov;33(11):1073-83. PubMed PMID: 14660172.

2: Danielsson BR, Sköld AC, Johansson A, Dillner B, Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol. 2003 Dec 1;193(2):168-76. PubMed PMID: 14644619.

3: Farkas A, Leprán I, Papp JG. Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits. Eur J Pharmacol. 1998 Apr 10;346(2-3):245-53. PubMed PMID: 9652366.

4: Darpö B, Edvardsson N. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. J Cardiovasc Pharmacol. 1995 Aug;26(2):198-206. PubMed PMID: 7475043.

5: Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res. 1993 Dec;27(12):2186-93. PubMed PMID: 8313427.